Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients

Abstract

Objective:To evaluate and compare the effects on high-sensitivity C-reactive protein (hs-CRP) levels and lipid profile of atorvastatin and rosuvastatin in obese type 2 diabetes mellitus (T2DM) patients.Materials and Methods:A total of 40 subjects with 20 in each group were randomly allocated to two groups. Group 1 patients received atorvastatin and that of Group 2 rosuvastatin treatment for 6 months. The patients were administered atorvastatin (40-80 mg) and rosuvastatin(10-40 mg) in accordance to their LDL-C status as per NCEP-ATP III guidelines. The parameters studied were, hs-CRP and lipid profile comprising LDL-C, HDL-C, TG and TC.Results:Results obtained from the study, clearly indicate that atorvastatin (A) as well as rosuvastatin(R) have significant effect on lowering of hs-CRP levels (for A P=0.001; for R P=0.002), reducing LDL-C levels (for A P=0.008; for R P=0.001), elevating HDL-C levels (for A P=0.02; for R P=0.001) along with reducing TC (for A P=0.003; for R P=0.002) and TG (for A P=0.000; for R P=0.000) levels in obese T2DM patients. It is also seen that there is no significant (P>0.05) difference in effect of atorvastatin and rosuvastatin in lowering of hs-CRP levels, elevating HDL-C levels and reducing TG levels in obese T2DM patients. However, percentage lowering of LDL-C (P=0.000) and TC (P=0.001) by rosuvastatin is to a greater extent than that caused by atorvastatin in these patients.Conclusions:Thus this study throws light on the fact that rosuvastatin should be preferred over atorvastatin in obese T2DM patients in whom LDL-C and TC levels are deviated from normal reference values. In rest of obese T2DM either of atorvastatin or rosuvastatin can be employed to lower hs-CRP levels, to elevate HDL-C levels or to reduce TG levels.

Induction of Heat Shock Proteins in the Therapy of Type 2 Diabetes and Metabolic Syndrome

“…The reduction in inflammation cannot be understated, as cardiovascular disease is indeed the major cause of mortality in these disease states ( Haffner, 2006 ). The 54% drop in hs-CRP compares favorably with the drop observed with atorvastatin (35%) in t2DM patients ( Sindhu et al, 2011 ).…”

Modulatory Effect of Lovastatin on Therapeutic Efficiency of Conventional Antidiabetics on Pancreatic and Cardiovascular Complications of Diabetes

“…Effect of LOVA on CRP and IL-6 levels is important in diabetes management as serum CRP and IL-6 levels are indices of acute phase inflammation and early markers of diabetes incidence 50 . CRP is synthesized in the liver under the influence of factors released from adipocytes in dyslipidemic conditions and can exacerbate complement-dependent ischemic necrosis leading to myocardial infarcts 51,52 . Moreover, the pro-inflammatory cytokine IL-6 is an important mediator in the pathogenesis of diabetes and diabetic complications.…”

Antihyperglycaemic effect of aqueous extract of Moringa oleifera leaf on alloxan-induced diabetic male Wistar rats

“…Latex particles coated with specific anti-CRP are agglutinated when mixed with sample containing CRP. The agglutination causes an absorbance change, depending on the CRP contents of the sample that can be quantified by comparison from a calibrator of known CRP concentration (Sindhu et al, 2011). Turbilatex method with high sensitivity and specificity was used.…”